1.1 Research Scope 1.2 Market Segmentation 1.3 Research Objectives 1.4 Research Methodology 1.4.1 Research Process 1.4.2 Data Triangulation 1.4.3 Research Approach 1.4.4 Base Year 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections 1.5.2 Covid-19 Impact: Commodity Prices Indices 1.5.3 Covid-19 Impact: Global Major Government Policy 1.6 The Covid-19 Impact on Anti-Obesity Prescription Drugs Industry 1.7 COVID-19 Impact: Anti-Obesity Prescription Drugs Market Trends 2 Global Anti-Obesity Prescription Drugs Quarterly Market Size Analysis 2.1 Anti-Obesity Prescription Drugs Business Impact Assessment - COVID-19 2.1.1 Global Anti-Obesity Prescription Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 2.1.2 Global Anti-Obesity Prescription Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 2.2 Global Anti-Obesity Prescription Drugs Quarterly Market Size 2020-2021 2.3 COVID-19-Driven Market Dynamics and Factor Analysis 2.3.1 Drivers 2.3.2 Restraints 2.3.3 Opportunities 2.3.4 Challenges 3 Quarterly Competitive Assessment, 2020 3.1 Global Anti-Obesity Prescription Drugs Quarterly Market Size by Manufacturers, 2019 VS 2020 3.2 Global Anti-Obesity Prescription Drugs Factory Price by Manufacturers 3.3 Location of Key Manufacturers Anti-Obesity Prescription Drugs Manufacturing Factories and Area Served 3.4 Date of Key Manufacturers Enter into Anti-Obesity Prescription Drugs Market 3.5 Key Manufacturers Anti-Obesity Prescription Drugs Product Offered 3.6 Mergers & Acquisitions, Expansion Plans 4 Impact of Covid-19 on Anti-Obesity Prescription Drugs Segments, By Type 4.1 Introduction 1.4.1 Orlistat 1.4.2 Phentermine and Topiramate 1.4.3 Bupropion and Naltrexone 1.4.4 Lorcaserin 1.4.5 Liraglutide 4.2 By Type, Global Anti-Obesity Prescription Drugs Market Size, 2019-2021 4.2.1 By Type, Global Anti-Obesity Prescription Drugs Market Size by Type, 2020-2021 4.2.2 By Type, Global Anti-Obesity Prescription Drugs Price, 2020-2021 5 Impact of Covid-19 on Anti-Obesity Prescription Drugs Segments, By Application 5.1 Overview 5.5.1 Pediatric 5.5.2 Adult 5.2 By Application, Global Anti-Obesity Prescription Drugs Market Size, 2019-2021 5.2.1 By Application, Global Anti-Obesity Prescription Drugs Market Size by Application, 2019-2021 5.2.2 By Application, Global Anti-Obesity Prescription Drugs Price, 2020-2021 6 Geographic Analysis 6.1 Introduction 6.2 North America 6.2.1 Macroeconomic Indicators of US 6.2.2 US 6.2.3 Canada 6.3 Europe 6.3.1 Macroeconomic Indicators of Europe 6.3.2 Germany 6.3.3 France 6.3.4 UK 6.3.5 Italy 6.4 Asia-Pacific 6.4.1 Macroeconomic Indicators of Asia-Pacific 6.4.2 China 6.4.3 Japan 6.4.4 South Korea 6.4.5 India 6.4.6 ASEAN 6.5 Rest of World 6.5.1 Latin America 6.5.2 Middle East and Africa 7 Company Profiles 7.1 F Hoffmann La Roche Ltd 7.1.1 F Hoffmann La Roche Ltd Business Overview 7.1.2 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Quarterly Production and Revenue, 2020 7.1.3 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Introduction 7.1.4 F Hoffmann La Roche Ltd Response to COVID-19 and Related Developments 7.2 Orexigen Therapeutics 7.2.1 Orexigen Therapeutics Business Overview 7.2.2 Orexigen Therapeutics Anti-Obesity Prescription Drugs Quarterly Production and Revenue, 2020 7.2.3 Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Introduction 7.2.4 Orexigen Therapeutics Response to COVID-19 and Related Developments 7.3 Novo Nordisk A/s 7.3.1 Novo Nordisk A/s Business Overview 7.3.2 Novo Nordisk A/s Anti-Obesity Prescription Drugs Quarterly Production and Revenue, 2020 7.3.3 Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Introduction 7.3.4 Novo Nordisk A/s Response to COVID-19 and Related Developments 7.4 Arena Pharmaceuticals 7.4.1 Arena Pharmaceuticals Business Overview 7.4.2 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Quarterly Production and Revenue, 2020 7.4.3 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Introduction 7.4.4 Arena Pharmaceuticals Response to COVID-19 and Related Developments 7.5 Glaxosmithkline 7.5.1 Glaxosmithkline Business Overview 7.5.2 Glaxosmithkline Anti-Obesity Prescription Drugs Quarterly Production and Revenue, 2020 7.5.3 Glaxosmithkline Anti-Obesity Prescription Drugs Product Introduction 7.5.4 Glaxosmithkline Response to COVID-19 and Related Developments 7.6 Vivus 7.6.1 Vivus Business Overview 7.6.2 Vivus Anti-Obesity Prescription Drugs Quarterly Production and Revenue, 2020 7.6.3 Vivus Anti-Obesity Prescription Drugs Product Introduction 7.6.4 Vivus Response to COVID-19 and Related Developments 7.7 Boehringer Ingelheim 7.7.1 Boehringer Ingelheim Business Overview 7.7.2 Boehringer Ingelheim Anti-Obesity Prescription Drugs Quarterly Production and Revenue, 2020 7.7.3 Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Introduction 7.7.4 Boehringer Ingelheim Response to COVID-19 and Related Developments 7.8 Alizyme 7.8.1 Alizyme Business Overview 7.8.2 Alizyme Anti-Obesity Prescription Drugs Quarterly Production and Revenue, 2020 7.8.3 Alizyme Anti-Obesity Prescription Drugs Product Introduction 7.8.4 Alizyme Response to COVID-19 and Related Developments 8 Supply Chain and Sales Channels Analysis 8.1 Anti-Obesity Prescription Drugs Supply Chain Analysis 8.1.1 Anti-Obesity Prescription Drugs Supply Chain Analysis 8.1.2 Covid-19 Impact on Anti-Obesity Prescription Drugs Supply Chain 8.2 Distribution Channels Analysis 8.2.1 Anti-Obesity Prescription Drugs Distribution Channels 8.2.2 Covid-19 Impact on Anti-Obesity Prescription Drugs Distribution Channels 8.2.3 Anti-Obesity Prescription Drugs Distributors 8.3 Anti-Obesity Prescription Drugs Customers 9 Key Findings 10 Appendix 10.1 About Us 10.2 Disclaimer

List of Tables Table 1. Overview of the World Economic Outlook Projections Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity) Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise) Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise) Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise) Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise) Table 7. Covid-19 Impact: Global Major Government Policy Table 8. The Covid-19 Impact on Anti-Obesity Prescription Drugs Assessment Table 9. COVID-19 Impact: Anti-Obesity Prescription Drugs Market Trends Table 10. COVID-19 Impact Global Anti-Obesity Prescription Drugs Market Size Table 11. Global Anti-Obesity Prescription Drugs Market Size Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (K g) Table 12. Global Anti-Obesity Prescription Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026, (USD/MT) Table 13. Global Anti-Obesity Prescription Drugs Quarterly Market Size, 2020 (US$ Million) & (K g) Table 14. Global Anti-Obesity Prescription Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million) Table 15. Global Anti-Obesity Prescription Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (K g) Table 16. Global Anti-Obesity Prescription Drugs Market Growth Drivers Table 17. Global Anti-Obesity Prescription Drugs Market Restraints Table 18. Global Anti-Obesity Prescription Drugs Market Opportunities Table 19. Global Anti-Obesity Prescription Drugs Market Challenges Table 20. Key Manufacturers Anti-Obesity Prescription Drugs Quarterly Revenue, 2019 VS 2020 (US$ Million) Table 21. Top Manufacturers, Anti-Obesity Prescription Drugs Market Size, 2019 (K g) & (US$ Million) Table 22. Anti-Obesity Prescription Drugs Factory Price by Manufacturers 2020 (USD/MT) Table 23. Location of Key Manufacturers Anti-Obesity Prescription Drugs Manufacturing Plants Table 24. Key Manufacturers Anti-Obesity Prescription Drugs Market Served Table 25. Date of Key Manufacturers Enter into Anti-Obesity Prescription Drugs Market Table 26. Key Manufacturers Anti-Obesity Prescription Drugs Product Type Table 27. Mergers & Acquisitions, Expansion Plans Table 28. Global Anti-Obesity Prescription Drugs Market Size by Type, 2020, (US$ Million) Table 29. Global Anti-Obesity Prescription Drugs Market Size by Type, 2020 (K g) Table 30. Global Anti-Obesity Prescription Drugs Price: by Type, 2020-2021 (USD/MT) Table 31. Global Anti-Obesity Prescription Drugs Market Size by Application: 2020-2021 (US$ Million) Table 32. Global Anti-Obesity Prescription Drugs Market Size by Application, 2020-2021 (K g) Table 33. Global Anti-Obesity Prescription Drugs Price: by Application, 2020-2021 (USD/MT) Table 34. Global Anti-Obesity Prescription Drugs Market Size by Region, 2019-2021 (US$ Million) Table 35. Global Anti-Obesity Prescription Drugs Market Size by Region, 2019-2021 (K g) Table 36. By Country, North America Anti-Obesity Prescription Drugs Market Size, 2019-2021 (US$ Million) Table 37. By Country, North America Anti-Obesity Prescription Drugs Market Size, 2019-2021 (K g) Table 38. US Anti-Obesity Prescription Drugs Market Size, 2019-2021 (US$ Million) & (K g) Table 39. Canada Anti-Obesity Prescription Drugs Market Size, 2019-2021 (US$ Million) & (K g) Table 40. Macroeconomic Indicators of Europe (Germany, France, UK and Italy) Table 41. By Country, Europe Anti-Obesity Prescription Drugs Market Size, 2019-2021 (US$ Million) Table 42. By Country, Europe Anti-Obesity Prescription Drugs Market Size, 2019-2021 (K g) Table 43. Germany Anti-Obesity Prescription Drugs Market Size, 2019-2021 (US$ Million) & (K g) Table 44. France Anti-Obesity Prescription Drugs Market Size, 2019-2021 (US$ Million) & (K g) Table 45. UK Anti-Obesity Prescription Drugs Market Size, 2019-2021 (US$ Million) & (K g) Table 46. Italy Anti-Obesity Prescription Drugs Market Size, 2019-2021 (US$ Million) & (K g) Table 47. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN) Table 48. By Region, Asia-Pacific Anti-Obesity Prescription Drugs Market Size, 2019-2021 (US$ Million) Table 49. By Region, Asia-Pacific Anti-Obesity Prescription Drugs Market Size, 2019-2021 (K g) Table 50. China Anti-Obesity Prescription Drugs Market Size, 2019-2021 (US$ Million) & (K g) Table 51. Japan Anti-Obesity Prescription Drugs Market Size, 2019-2021 (US$ Million) & (K g) Table 52. South Korea Anti-Obesity Prescription Drugs Market Size, 2019-2021 (US$ Million) & (K g) Table 53. India Anti-Obesity Prescription Drugs Market Size, 2019-2021 (US$ Million) & (K g) Table 54. ASEAN Anti-Obesity Prescription Drugs Market Size, 2019-2021 (US$ Million) & (K g) Table 55. Latin America Anti-Obesity Prescription Drugs Market Size, 2019-2021 (US$ Million) & (K g) Table 56. Middle East and Africa Anti-Obesity Prescription Drugs Market Size, 2019-2021 (US$ Million) & (K g) Table 57. F Hoffmann La Roche Ltd Business Overview Table 58. F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Production (K g), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 59. F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Table 60. F Hoffmann La Roche Ltd Response to COVID-19 and Related Developments Table 61. Orexigen Therapeutics Business Overview Table 62. Orexigen Therapeutics Anti-Obesity Prescription Drugs Production (K g), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 63. Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Table 64. Orexigen Therapeutics Response to COVID-19 and Related Developments Table 65. Novo Nordisk A/s Business Overview Table 66. Novo Nordisk A/s Anti-Obesity Prescription Drugs Production (K g), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 67. Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Table 68. Novo Nordisk A/s Response to COVID-19 and Related Developments Table 69. Arena Pharmaceuticals Business Overview Table 70. Arena Pharmaceuticals Anti-Obesity Prescription Drugs Production (K g), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 71. Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Table 72. Arena Pharmaceuticals Response to COVID-19 and Related Developments Table 73. Glaxosmithkline Business Overview Table 74. Glaxosmithkline Anti-Obesity Prescription Drugs Production (K g), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 75. Glaxosmithkline Anti-Obesity Prescription Drugs Product Table 76. Glaxosmithkline Response to COVID-19 and Related Developments Table 77. Vivus Business Overview Table 78. Vivus Anti-Obesity Prescription Drugs Production (K g), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 79. Vivus Anti-Obesity Prescription Drugs Product Table 80. Vivus Response to COVID-19 and Related Developments Table 81. Boehringer Ingelheim Business Overview Table 82. Boehringer Ingelheim Anti-Obesity Prescription Drugs Production (K g), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 83. Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Table 84. Boehringer Ingelheim Response to COVID-19 and Related Developments Table 85. Alizyme Business Overview Table 86. Alizyme Anti-Obesity Prescription Drugs Production (K g), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 87. Alizyme Anti-Obesity Prescription Drugs Product Table 88. Alizyme Response to COVID-19 and Related Developments Table 89. Anti-Obesity Prescription Drugs Distributors List Table 90. Anti-Obesity Prescription Drugs Customers List Table 91. Covid-19 Impact on Anti-Obesity Prescription Drugs Customers List of Figures Figure 1. Anti-Obesity Prescription Drugs Product Picture Figure 2. Anti-Obesity Prescription Drugs Market Segmentation Figure 3. Research Objectives Figure 4. Research Process Figure 5. Data Triangulation Figure 6. Research Approach Figure 7. Commodity Prices-Metals Price Indices Figure 8. Commodity Prices- Precious Metal Price Indices Figure 9. Commodity Prices- Agricultural Raw Material Price Indices Figure 10. Commodity Prices- Food and Beverage Price Indices Figure 11. Commodity Prices- Fertilizer Price Indices Figure 12. Commodity Prices- Energy Price Indices Figure 13. G20+: Economic Policy Responses to COVID-19 Figure 14. Global Anti-Obesity Prescription Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million) Figure 15. Global Anti-Obesity Prescription Drugs Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%) Figure 16. Global Anti-Obesity Prescription Drugs Market Size, Quarterly Growth, 2020-2021 (%) Figure 17. Global Anti-Obesity Prescription Drugs Market Size, Market Share by Type, 2019 VS 2020 (%) Figure 18. Global Anti-Obesity Prescription Drugs Market Size, Market Share by Application, 2019 VS 2020 (%) Figure 19. Global Anti-Obesity Prescription Drugs Market Size Market Share by Region, 2019 VS 2020 (%) Figure 20. United States Composite PMI and GDP Figure 21. Eurozone Composite PMI and GDP Figure 22. Eurozone Core v. Periphery PMI Output Indices Figure 23. Core v. Periphery PMI Employment Indices Figure 24. UK Composite PMI and GDP Figure 25. Caixin China Composite Output Index Figure 26. Caixin China General Services Business Activity Index Figure 27. Japan Composite Output Index Figure 28. South Korea Manufacturing PMI Figure 29. India Composite Output Index Figure 30. ASEAN Manufacturing PMI Figure 31. By Region, Asia-Pacific Anti-Obesity Prescription Drugs Market Size Market Share, 2019-2021

F Hoffmann La Roche Ltd Orexigen Therapeutics Novo Nordisk A/s Arena Pharmaceuticals Glaxosmithkline Vivus Boehringer Ingelheim Alizyme